Holen Sie sich die Stockscreener-App
14.61
0.41%
0.06
Vorhandelsmarkt:
14.52
-0.09
-0.62%
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
Top Executives Cash In on MoonLake Immunotherapeutics Stock! - TipRanks
MOONLAKE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Understanding the Setup: (MLTX) and Scalable Risk - news.stocktradersdaily.com
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Ready to Jump After Recent Trade: MoonLake Immunotherapeutics (MLTX) - Setenews
MLTX DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important December 15 Deadline in Securities Class ActionMLTX - marketscreener.com
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of MoonLake Immunotherapeutics, Inc. Investors - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SueWallSt Podcast Series Launches With Focus on MoonLake Immunotherapeutics (MLTX) Fraud Allegations - ACCESS Newswire
Marshall Wace LLP Sells 111,706 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
Shareholders SueWallSt in New Class Action Against MoonLake ImmunotherapeuticsAct Now - ACCESS Newswire
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash - AOL.com
MLTX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important December 15 Deadline in Securities Class ActionMLTX - marketscreener.com
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - marketscreener.com
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER - GlobeNewswire
2025-12-07 | Did You Lose Money on MoonLake Immunotherapeutics (MLTX)? Levi & Korsinsky Urges Investors to Act Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - The Malaysian Reserve
MLTX 9-DAY DEADLINE ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire
MLTX SECURITIES ALERT: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses of Important December 15 Securities Class Action Deadline - marketscreener.com
Are MoonLake (MLTX) Securities Lawsuits Quietly Reframing the Credibility of Its Drug Innovation Story? - simplywall.st
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Se - GuruFocus
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
MLTX FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class ActionMLTX - marketscreener.com
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
MoonLake Immunotherapeutics Target of Unusually Large Options Trading (NASDAQ:MLTX) - MarketBeat
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Why MoonLake Immunotherapeutics (MLTX) Is Up 9.2% After Lawsuits Challenging Sonelokimab Claims And What's Next - Yahoo Finance
MoonLake Immunotherapeutics (MLTX) Valuation After Class Action Lawsuits and Sonelokimab Trial Setbacks - simplywall.st
Levi & Korsinsky Helps Shareholders SueWallSt After MoonLake Immunotherapeutics Stock Drops - ACCESS Newswire
Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class - GlobeNewswire
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.3%Still a Buy? - MarketBeat
Cantor Fitzgerald Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
FDA moving to one trial for approval could be positve for MoonLake, says Cantor - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - WV News
181,600 Shares in MoonLake Immunotherapeutics $MLTX Acquired by Decheng Capital LLC - MarketBeat
Levi & Korsinsky Invites Investors to SueWallSt After MoonLake Immunotherapeutics Stock Collapse - ACCESS Newswire
MoonLake Immunotherapeutics Sued for Securities Law - GlobeNewswire
MOONLAKE STOCK ALERT: MoonLake Immunotherapeutics (MLTX) Investors Reminded to Contact BFA Law Prior to the December 15 Deadline in Securities Fraud Class Action - marketscreener.com
A better buy-in window may exist right now for MoonLake Immunotherapeutics (MLTX) - Setenews
MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities - GlobeNewswire
MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake’s SLK - GlobeNewswire
MLTX Deadline: MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - lelezard.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and - GlobeNewswire
MoonLake Immunotherapeutics Sued for Securities Law ViolationsContact Levi & Korsinsky Before December 15, 2025 to Discuss Your RightsMLTX - PR Newswire
MLTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority - Finviz
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - MarketScreener
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
The Gross Law Firm Reminds MoonLake Immunotherapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025MLTX - PR Newswire
MoonLake Immunotherapeutics (NASDAQ: MLTX) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - cnhinews.com
MLTX LEGAL ALERT: MoonLake Immunotherapeutics Hit with - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeut - GuruFocus
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):